Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Driehaus Micro Cap Growth Strategy 2024 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Driehaus Micro Cap Growth Strategy)

Primary Source Intelligence • Q3 2024 Letter Analysis

Driehaus Micro Cap Growth Strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Driehaus Micro Cap Growth Strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+8.21%

Annualized+20.6%

Digest Analysis

Quick Take

"Small cap growth strategy capitalizing on historically cheap valuations and Fed rate cuts. Strong biotech performance offset by tech weakness in Q3."

Executive Summary

Driehaus Micro Cap Growth strategy gained 8.21% in Q3 2024, slightly underperforming the Russell Microcap Growth benchmark by 36 basis points but outperforming year-to-date by 14.71%. The manager maintains a positive outlook for small caps based on several compelling factors: small caps trade at historically deep discount to large caps similar to early 2000s, Fed began rate cutting cycle which historically benefits small caps, and earnings growth is expected to accelerate. Healthcare led performance with 19.2% gains driven by biotech positions with promising clinical data, while technology detracted due to AI-related pullbacks. The strategy benefits from themes including AI infrastructure spending, reshoring, and biotechnology innovation. Portfolio positioning remains overweight industrials, consumer discretionary, financials and materials while underweight healthcare and technology. Key risks include potential economic weakness, earnings deterioration, and geopolitical tensions, though the manager believes current economic conditions support continued growth without recession.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

Moderate-high conviction evidenced by concentrated top 5 holdings representing 11.7% of portfolio, clear thesis on small cap opportunity with specific catalysts and timeframes. Manager provides detailed analysis of valuation discount, Fed cycle impacts, and earnings expectations. However, diversified 119-position portfolio and hedged language around risks prevents higher scoring.

Growth Outlook

65%

BearishBullish

Bullish (65%)

Manager expresses constructive optimism about markets with positive outlook for U.S. equities. Believes strengths outweigh bearish concerns and sees economy, inflation and earnings trending favorably. However, acknowledges multiple risk factors including economic weakness, political dysfunction and geopolitical issues.

Risk Appetite

45%

DefensiveAggressive

Balanced (45%)

Portfolio maintains sector overweights and underweights with selective positioning. Reduced technology exposure during quarter due to weakness but increased healthcare allocation. Strategy shows measured risk appetite with 119 holdings and diversified sector exposure rather than aggressive concentration.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

Limited net deployment activity with cash remaining low at 0.3%. Manager rotated between sectors, reducing technology exposure while increasing healthcare allocation, but this represents rotation rather than net new capital deployment. Some new positions added in retail and homebuilding but overall activity appears balanced.

Forward Guidance

55%

CautiousExpansionary

Neutral (55%)

Manager indicates continued positive positioning with selective deployment. Maintains overweight positions in preferred sectors while reducing exposure to weaker areas like technology. Forward guidance suggests continued investment in themes like AI infrastructure and biotechnology with measured optimism.

Language Signal

60%

BearishBullish

Balanced (60%)

Language is predominantly positive with frequent use of opportunity, attractive, strength, and positive outlook. Discusses compelling valuation discount, supportive environment, and favorable trends. Risk language is present but balanced with opportunity framing rather than dominating the narrative.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

Manager acknowledges multiple risk factors including economic weakness, earnings deterioration, political dysfunction, and geopolitical tensions. However, risks are mentioned as considerations rather than central concerns, and manager explicitly states belief that strengths outweigh bearish concerns.

Opportunity Density

70%

ScarceAbundant

Abundant (70%)

Manager sees attractive opportunity set across multiple themes including AI infrastructure, biotechnology innovation, and small cap valuation discount. Identifies specific sectors and themes with compelling prospects while maintaining selective approach. Strong conviction in small cap opportunity set despite some sector-specific challenges.

Time Horizon

65%

Short-TermLong-Term

Multi-Year (65%)

Multi-year investment horizon evidenced by focus on secular themes like AI infrastructure, biotechnology clinical development, and small cap cycle dynamics. Manager discusses historical patterns and long-term earnings growth while acknowledging some near-term catalysts like Fed cuts and clinical trial results.